{
    "ticker": "NBY",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage biotechnology company focused on harnessing the immune system to address cancer, infectious diseases, and other serious conditions. Founded in 2015 and headquartered in Culver City, California, NantKwest is pioneering the development of its proprietary natural killer (NK) cell therapies. These therapies are designed to enhance the body\u2019s natural immune response to target and destroy malignant cells, offering a promising avenue for treatment in areas where traditional therapies may be ineffective. NantKwest's innovative approach includes the use of genetically modified NK cells, which have shown potential in clinical trials for treating various types of cancers, including solid tumors and hematologic malignancies. The company is committed to advancing its research and development capabilities and aims to bring its leading-edge therapies to market through strategic partnerships and collaborations. NantKwest's mission is to transform healthcare through the development of potent immunotherapies that can significantly improve patient outcomes and provide hope to those battling life-threatening diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Culver City, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "Patrick Soon-Shiong",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://investors.nantkwest.com",
    "key_executives": [
        {
            "name": "Patrick Soon-Shiong",
            "position": "CEO"
        },
        {
            "name": "Gordon M. Sanghera",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "NantKwest NK Cell Therapy"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Pioneering Immunotherapy Solutions",
        "meta_description": "Explore NantKwest, Inc., a leader in developing innovative NK cell immunotherapies for cancer and infectious diseases. Learn about our mission and advancements in biotechnology.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "Biotechnology",
            "NK Cells",
            "Cancer Treatment",
            "Infectious Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is NantKwest known for?",
            "answer": "NantKwest is known for its pioneering work in developing natural killer (NK) cell therapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "Patrick Soon-Shiong is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Culver City, California, USA."
        },
        {
            "question": "What types of therapies does NantKwest develop?",
            "answer": "NantKwest develops NK cell immunotherapies aimed at treating cancer and infectious diseases."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "NVTA"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "ABBV",
        "GILD"
    ]
}